Nyxoah (NYXH) has released an update.
Nyxoah celebrated its clinical and regulatory milestones by ringing the closing bell on Nasdaq, marking progress towards the American launch of its Genio system for treating Obstructive Sleep Apnea (OSA). The company has completed its FDA registration application, with approval expected by the end of 2024 and a commercial launch in the US slated for early 2025, backed by over 85 million euros in funding. Nyxoah has also established a US commercial team, anticipating a strong market entry following positive data from its DREAM study.
For further insights into NYXH stock, check out TipRanks’ Stock Analysis page.
